CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 07th November, 2023

To, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 (Maharashtra)

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Tuesday, 07th November, 2023 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Tuesday, 07th November, 2023 at the Corporate Office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) which commenced at 01:00 P.M. and concluded at 05:00 P.M. inter-alia, transacted the following business:

1. Approved the Un-audited Financial Results of the company for the quarter and half year ended on 30th September, 2023 along with the Statement of Assets and Liabilities as on 30th September, 2023 and Statement of Cash Flow for the half year ended on 30th September, 2023 and took on record the Limited Review Report thereon. (Enclosed as Annexure-A)

Further, the extract of the Un-audited Financial Results would also be published in the newspapers in compliance with Regulation 47 of Listing Regulations.

TRADING WINDOW:

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from Friday, 10th November, 2023 for all Designated Persons and their relatives.

You are requested to kindly take the same on record.

Thanking you, Yours faithfully,

FOR SARDA PROTEINS LTD

pany Secretary

AMIT KUMAR MODI **COMPANY SECRETARY & COMPLIANCE OFFICER**

M.NO.: A29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan) Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) Contact No.: +91-7737822222; E Mail: sardaproteins@yahoo.com; Web: www.sardaproteins.com

SKAGARWAL & ASSOCIATES

Chartered Accountants

111, Ist Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)

Mob: 9828115580 | Email: cabhiwadi@gmail.com

Limited Review Report Unaudited Standalone Quarterly Results

To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of SARDA PROTEINS LTD for the Quarter and Half Year ended on 30th September, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S K Agarwal & Associates

Chartered Accountants

FRN: 014841C

CA Sushil Kumar Agarwal

Partner

M. No.: 403073

UDIN: 23403073BGXLAK3585

Place: Jaipur Date: 07.11.2023

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan) Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2023

			O		Rs.in Lakh Half Year ended Year ended			
No.)	30.09.2023	Quarter ended 30.09.2023 30.06.2023 30.09.2022			Half Year ended		
		Un-Audited		30,09,2022 Un-Audited	30.09.2023 Un-Audited	30.09.2022 Un-Audited	31.03.202	
1,	Revenue from Operations	CH-ABUILEU	23.58	279.21	23.58	279.21	Audited	
11.	Other Income	4.13	4.09	2.48	8.22	7.65	579.	
111.	Total Income (I+II)						15.9	
IV.	Expenses:	4.13	27.67	281.69	31.80	286.86	595.	
	Cost of Material Consumed							
	Purchase of Stock -in- Trade	•	-		-	•		
	Changes in Inventories (Cirich A.C. 1 1995)		23.63	275.57	23.63	275.57	571.	
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade) Employee Benefit Expenses		-			• 1		
	Finance Cost	2.62	2.74	3.31	5.36	6.75	13.4	
		•						
	Depreciation and Amoritsation Expenses	•	-			•		
	Other expenses	2.02	1.55	2.54	3.57	4.05	8.9	
	Total Expenses (IV)	4.64	27.92	281.42	32.56	286.37	594.	
	Profit/(Loss) before Exceptional and Extraordinary Items and Tax	-				200.01	Contract designation	
	(III-IV)	(0.51)	(0.25)	0.27	(0.76)	0.49	1.2	
	Exceptional Items	- (44,1)	(0.23)	0.21	(0.70)	0.49	1.4	
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	(0.51)	(0.25)	0.27	(0.76)	0.49	1.2	
	Extraordinary Items	(54.7)	(0.2.5)		(0.70)	0.47	1.4	
IX.	Profit/(Loss) before Tax (V-VI)	(0.51)	(0.25)	0.27	(0.76)	0,49	1.2	
X	Tax Expense:	(0.51)	(0.23)	0.21	(0.70)	0.49	1.4	
	(1) Current Tax	-	-					
	(2) Deferred Tax					-		
	Profit/(Loss) for the period from Continuing Operations (VII-VIII)						4.6	
ΧI		(0.51)	(0.25)	0.27	(0.76)	0.49	(2.1	
XII	Profit/(Loss) from Discontinued Operations		(0.23)	0.27	(0.70)		(3.3	
XIII.	Tax Expenses of Discontinued Operations		-					
XIV.			-					
XV	Profit/(Loss) for the Period (IX+XII)	(0.51)	(0.25)	0.27	- (0.70)		•	
XVI		(0.51)	(0.23)	0.21	(0.76)	0.49	(3.3	
	A (i) Items will not be reclassified to Profit or Loss	-	-					
	(ii) Income Tax relating to items that will not be reclassified to			<u> </u>	-	•		
	Profit or Loss			_				
	B (i) Items will be reclassified to Profit or Loss	-		<u> </u>				
	(ii) Income Tax relating to items that will be reclassified to Profit		-		-		-	
	or Loss							
	Total Comprehensive Income for the period		 					
	(XIII+XIV)(Comprising Profit (Loss) and other Comprehensive							
XVI	I. Income for the period)	(0.51)	(0.25)	0.27	(0.76)	0.49	(2.2	
	Paid Up Equity Share Capital, Equity Shares of Face Value Rs. 10	(0.51)	1 (0.23)	0.27	(0.76)	0.49	(3.3	
	each	172.59	172.59	172.59	172.59	172 50	174	
XVII	II Earnings per Equity Share	112.37	112.37	112.39	172.39	172.59	172.5	
	(1) Basic	(0.03)	(0.01)	0.02	(0.04)	0.03	(0.4	
			· · · · · · · · · · · · · · · · · · ·				(0.1	
	(2) Diluted	(0.03)	(0.01)	0.02	(0.04)	0.03		

Place: Jaipur

Date: 07-Nov-2023 UDIN: 23403073861X

on behalf of the Board Sarda Proteins Ltd PRO

Deepak Data (DIN: 01672415)

Managing Director

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan) Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

CIN: L15142RJ1991PLC006353

STATEMENT OF ASSETS AND LIABLITIES AS AT 30TH SEPTEMBER 2023

Rs in Lakhs Particulars Six Months ended Year ended 30.09.2023 30.09.2022 31.03.2023 A. ASSETS Un-Audited Un-Audited Audited Non-Current Assets a) Property, Plant and Equipment b) Capital work in progress 0.01 0.01 0.01 c) Investment Property d) Goodwill e) Other Intangible Assets f) Intangible Assets under Development g) Biological Assets other than bearer plants h) Financial Assets i) Investments ii) Trade Receivables 0.13 0.13 0.13 iii) Loans i) Deferred Tax Assets (net) j) Other non-current Assets 13.49 18.09 13.49 Current Assets a) Inventories b) Financial Assets . _ i) Investments ii) Trade Receivables iii) Cash and Cash Equivalents 18.31 iv) Bank Balances and other than (iii) above 0.25 0.25 v) Loans 6.29 2.51 18.19 v) Others 205.00 205.00 205.00 c) Current Tax Assets (net) 13.00 3.38 d) Other Current Assets Total Assets 237.92 B. EQUITY AND LIABILITIES 244.30 240.45 Equity a) Equity Share Capital b) Other Equity 250.45 250.45 250.45 Liablities (15.86)(11.31)(15.10)Non current Liabilities a) Financial Liablities i) Borrowings ii) Trade Payables A) Total Outstanding dues to MSEs B) Total Outstanding dues to Creditors other than MSEs iii) Other Financial Liabilities b) Provisions 3.24 3.00 c) Deferred Tax Liablities (net) 2.79 d) Other Non Current Liablities Current Liablities . a) Financial Liablities i) Borrowings ii) Trade Payables _ A) Total Outstanding dues to MSEs B) Total Outstanding dues to Creditors other than MSEs 0.21 1.33 iii) Other Financial Liabilities • b) Other Current Liabilities (0.12)0.83 2.31 c) Provisions d) Current Tax Liablities (net) Total Equity and Liabilites 244.30 237.92 240,45

Place: Jaipur

on behalf of the Board PRO Sarda Proteins Ltd

JAIPUR

Decpak Data (DIN: 01672415)

Managing Director

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)

Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

CIN: 1.15142RJ1991PLC006353

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2023

Rs in Lakhs

		Six Mont	Year ended	
	Particulars	39.09.2823 Un-Audited	39,09,2022	31,03,202
-	(LEIL DI ANY IN ALL ANY		Un-Audited	Andited
	CASH FLOW FROM OPERATING ACTIVITIES	-		
	Net Profit before Tax and Extraordinary Items	(0.76)	0.49	1.2
٨.	ADJUSTMENT FOR			
	Depreciation	-		-
	Interest Received	(8.22)	(7.65)	(15.9
	Profit on Sale of Investment		•	A STATE OF THE PARTY OF T
	Dividend			4
	(Profit) /Loss on sale of Fixed Assets	- 1	•	-
	Interest Paid	-	-	-
	Operating Profit/(Loss) before Working Capital Charges	(8.98)	(7.16)	(14.6
	ADJUSTMENT FOR:		The second second	
	Trade and other Receivables	-	(28.86)	(13.9
	Other Current Assets/ Liabilities	(11.84)		-
	Inventories		•	*
	Trade & other Payables	-	(1.45)	(1.5
	Other Non Current Assets/ Liabilities	0.45		7
	Cash Generated from Operations	(20.37)	(37,47)	(30.1
	Direct Taxes Paid	- 1201317	13.7.7	130
	Net Cash from Operating Activities	(20.37)	(37.47)	(30.1
В.	CASH FLOW FROM INVESTING ACTIVITIES		13.0007	100
	Capital Expenditure	-	-	
	Sale of Fixed Assets			-
	Profit/ (Loss) on sale of Fixed Assets			
	Profit on sale of Investment	-	-	
	Sale of Investment	-	_	-
	Interest Received	8.22	7.65	15.9
	Dividend Received	-	- 1.05	13,7
	Net Cash Received from Investing Activities	8.22	7.65	15.9
C.	CASH FLOW FROM FINANCING ACTIVITIES		7.05	13.7
	Proceeds from Long Term Borrowings	-		
	Proceeds from Short Term Borrowings	-		
	Interest Paid	-		A CONTRACTOR OF THE PARTY OF TH
	Net Cash Inflow/ (Outflow) from Financing Activities			-
	A Cash Innov (Outloon) from Financing Activities			-
	Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(12,15)	(29.82)	(14.1
	Cash & Cash Equivalants (Opening)	18.44	32.58	32.5
-	Cash & Cash Equivalants (Closing)	6.29	2.76	18.4

Notes:

- 1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 07th November, 2023.
- 2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- 3. Segment Results as per AS is not applicable as dealing in only one segment i.e. " Agro Products",
- 4. No Investor Complaints were received during the quarter ended 30-Sep-2023 nor any pending as on 01-Oct-2023.

5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

on behalf of the Board Sarda Proteins Ltd

Deepale Data (DIN: 01672415) Managing Director

Place: Jaipur

Date: 07-Nov-2023

UDIN: 234030 43BGXLAK358

100 100